Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
By J. Krejcik, T. Casneuf, I. Nijhof, Bie M. P. Verbist, Jaime Bald, T. Plesner, K. Syed, K. Liu, N. Donk, B. Weiss and 4 more. Blood, 2016
881 citations recorded by the source corpus.
Subfields: Hematology, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/ba48eaee2e48b92c4878e79668a2b3913edf8015
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
Citations in the corpus
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma (2017, background): “¶ These patients had at least one high-risk abnormality: del17p, t(4;14), or t(14;16).”